Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma (Q39501098)

12 September 2017

title

Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma (English)

1 reference

12 September 2017

Zhilong Ai

1 reference

12 September 2017

Hongtao Pan

1 reference

12 September 2017

Tao Suo

1 reference

12 September 2017

Chentao Lv

1 reference

12 September 2017

Yueqi Wang

1 reference

12 September 2017

Saixiong Tong

1 reference

12 September 2017

Houbao Liu

1 reference

12 September 2017

language of work or name

English

0 references

publication date

5 July 2011

1 reference

full work available at URL

12 September 2017

https://api.elsevier.com/content/article/PII:S0304383511003922?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

https://api.elsevier.com/content/article/PII:S0304383511003922?httpAccept=text/plain

8 December 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

8 December 2024

1 reference

12 September 2017

volume

310

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

181-187

1 reference

Introduction: the history of arsenic trioxide in cancer therapy.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Insight into the complex regulation of CD133 in glioma

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Targeting CD133 antigen in cancer

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

CD133 as a marker for cancer stem cells: progresses and concerns

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

CD133: molecule of the moment

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Characterization of a side population of cancer cells from human gastrointestinal system

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Deregulation of the Akt pathway in human cancer

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

The activation of Akt/PKB signaling pathway and cell survival.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Cancer stem cell-directed therapies: recent data from the laboratory and clinic

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

The cancer stem cell microenvironment and anti-cancer therapy.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Down-regulation of beta1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide decreases AKT protein in a caspase-dependent manner

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

Carcinogenetic process in gallbladder mucosa with pancreaticobiliary maljunction (Review)

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.06.035

8 December 2024

Identifiers

DOI

1 reference

12 September 2017

1 reference